NEW YORK, July 31, 2014 /PRNewswire/ -- The Galien Foundation today announced the 2014 nominees for the eighth annual Prix Galien USA Awards. The Prix Galien Award is considered the biomedical industry's highest accolade and recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines and devices.
This year brings the highest number of nominees since the inception of the Prix Galien USA. Nominees include biomedical products across three categories – biotechnology, pharmaceutical, and technology products – that advance the human condition and which were approved by the U.S. Food and Drug Administration (FDA) during the past five years.
Nominees for the Prix Galien USA 2014 Awards are: Best Biotechnology Product (Nominees)BOTOX® (onabotulinumtoxinA)Allergan, Inc.for Chronic Migraine patientsVoraxaze® (glucarpidase)BTG International Inc.Erwinaze® (asparaginase Erwinia chrysanthemi)
Jazz PharmaceuticalsFluMist® QuadrivalentMedImmune/AstraZeneca(influenza vaccine live, intranasal)HEMACORD™ (HPC, Cord Blood)New York Blood Center'sHoward P. Milstein Cord Blood CenterFlucelvax® (Influenza Virus Vaccine)
NovartisGattex® (teduglutide)NPS PharmaZaltrap® (ziv-aflibercept)SanofiJetrea® (ocriplasmin)ThromboGenicsBest Pharmaceutical Agent (Nominees)Ampyra® (dalfampridine)Acorda TherapeuticsOpsumit® (macitentan)Actelion Pharmaceuticals LtdOZURDEX®Allergan, Inc(dexamethasone intravitreal implant) 0.7 mgBELIVIQ® (lorcaserin HCl) CIVArena Pharmaceuticals, Inc. & Eisai Inc.Caprelsa® (vandetanib)AstraZenecaAdempas® (riociguat)Bayer HealthCareStivarga® (regorafenib)Bayer HealthCareTecfidera® (dimethyl fumarate)Biogen IdecSovaldi® (sofosbuvir)Gilead SciencesJakafi® (ruxolitinib)IncyteImbruvica® (ibrutinib)Janssen & Pharmacyclics Invokana® (canaglifozin)Janssen SIRTURO® (bedaquiline)JanssenXarelto® (rivaroxaban)Janssen & Bayer HealthCareZytiga® (abiraterone acetate)JanssenXtandi® (enzalutamide)Medivation & AstellasXalkori® (crizotinib)PfizerXeljanz® (tofacitinib)PfizerEliquis® (apixaban)Bristol-Myers Squibb & PfizerOxyContin®Purdue Pharma(reformulated oxycodone HCl controlled release)Latuda® (lurasidone HCI)Sunovion Pharmaceuticals Inc.Neupro® (Rotigotine Transdermal System)UCBVimpat® (lacosamide)UCB Best Medical Technology (Nominees)SERI® Surgical ScaffoldAllergan, Inc.VITEK® MS PlatformbioMérieux COMBIVENT® RESPIMAT®Boehringer Ingelheim(ipratropium bromide and albuterol)Inhalation SprayThe Alair™ Bronchial Thermoplasty SystemBoston ScientificPrecision Spectra™ Spinal CordBoston ScientificStimulator SystemsuperDimension™ Navigation SystemCovidien – Interventional Lung SolutionsMobi-C® Cervical DiscLDR Holding CorporationNovoTTF™ TherapyNovocurecoflex® Interlaminar Stabilization™ deviceParadigm Spine, LLCElecsys® Testosterone IIRoche Auvi-Q® (epinephrine injection, USP)SanofiTrevo® ProVue™ RetrieverStrykerCentraSight® Implantable Telescope TechnologyVisionCare Ophthalmic Technologies"Biomedical research can only exist when there are those who are willing to push innovation, extract understanding, and bring attention to the details," remarked Bruno Cohen, Chairman of the Galien Foundation. "This year's nominees are catalysts for the development of disease-altering advances through biopharmaceutical and medical technology innovation. It is upon these values that the Galien Foundation is predicated, and we're proud to honor those in the field who exemplify these same principles."
The Prix Galien USA Committee, comprised of 10 renowned leaders from the biomedical industry and academia, including five Nobel Laureates, is responsible for evaluating nominees. Winners will be honored at the Prix Galien USA Awards Ceremony on October 28, 2014 at 6:30 p.m., at the American Museum of Natural History in New York City. Registration for the 2014 Prix Galien USA Awards Ceremony is open and can be accessed here.
Galien Awards Committee 2014
About the Galien Foundation
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.
The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.
For more information visit www.galienfoundation.org.
Galien Foundation Media Contact:
Makovsky on behalf of The Galien Foundation
|SOURCE Galien Foundation|
Copyright©2014 PR Newswire.
All rights reserved